EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseVergleichsstudieÜbersichtsarbeitOpen Access

Eradication of Helicobacter pylori With Vonoprazan–Amoxicillin Dual Therapy as an Alternative for Bismuth‐Based Quadruple Therapy: A Systematic Review and Noninferiority Meta‐Analysis

Pedro Robson Costa Passos iD, Valbert Oliveira Costa Filho, Mariana Macambira Noronha iD, Melissa Cortez Braga Maia, Guilherme Grossi Lopes Cançado iD

Journal of Gastroenterology and Hepatology · 2026-09 · 41 (9) · 2545-2556

DOI: 10.1111/jgh.70565 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 11.07.2026. Verfasst von Pedro Robson Costa Passos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceará, Fortaleza, Ceará, Brazil. Hauptthemen laut MEDLINE: Sulfonamides, Helicobacter Infections, Helicobacter pylori, Pyrroles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Whether the efficacy of vonoprazan–amoxicillin dual therapy (VADT) for Helicobacter pylori eradication is clinically acceptable compared with guideline‐recommended bismuth‐based quadruple therapy (BQT) remains uncertain. Prior analyses have largely relied on superiority frameworks.

Methods

PubMed, EMBASE, and CENTRAL were searched through December 23, 2025, for randomized controlled trials (RCTs) comparing VADT with BQT for H. pylori eradication. Intention‐to‐treat and per‐protocol eradication were summarized through Bayesian meta‐analysis as absolute risk differences. Noninferiority margins were prespecified at −10%, −5%, and 0% (superiority). Adverse events (AEs) were evaluated as secondary outcomes. Evidence certainty was assessed using GRADE.

Results

Eighteen Asian RCTs (5866 participants) were included. In intention‐to‐treat analyses, VADT achieved an absolute eradication increase of +2.27% compared with BQT (95% credible interval [CrI] −1.34% to +5.71%). The posterior probability of noninferiority exceeded 99% for the −10% and −5% margins but declined to 90.41% at 0%. In per‐protocol analyses, eradication showed an absolute decrease of 0.28% (95% CrI −3.30% to +4.17%), with noninferiority probabilities exceeding 99% for the −10% and −5% margins, but declining to 56.43% at 0%. VADT was associated with significantly lower rates of dysgeusia, dizziness/headache, nausea/vomiting, and overall mild AEs. Evidence certainty was moderate for intention‐to‐treat noninferiority in Eastern populations and low or very low for all other Eastern and Western analyses.

Discussion

VADT may be a reasonable alternative in East Asian settings where tolerability or regimen simplicity is a priority, but evidence is insufficient to support generalization to Western or non‐Asian populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulfonamidesHelicobacter InfectionsHelicobacter pyloriPyrrolesAmoxicillinAnti-Bacterial AgentsBismuthProton Pump InhibitorsHumansDrug Therapy, CombinationRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

Helicobacter pyloriantibioticsdual therapynoninferiority

Substanzen

SulfonamidesvonoprazanPyrrolesAmoxicillinAnti-Bacterial AgentsBismuthProton Pump Inhibitors

Autor:innen und Institutionen

  • Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceará, Fortaleza, Ceará, Brazil.
  • Núcleo de Biomedicina (NUBIMED), Universidade Federal do Ceará, Fortaleza, Ceará, Brazil.
  • Instituto Alfa de Gastroenterologia, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
  • Department of Gastroenterology and Hepatology, Hospital da Polícia Militar de Minas Gerais, Belo Horizonte, Brazil.

ORCID-Profile: Pedro Robson Costa Passos, Mariana Macambira Noronha, Guilherme Grossi Lopes Cançado

Zitieren

APA

Passos, P. R. C., Filho, V. O. C., Noronha, M. M., Maia, M. C. B., & Cançado, G. G. L. (2026). Eradication of Helicobacter pylori With Vonoprazan–Amoxicillin Dual Therapy as an Alternative for Bismuth‐Based Quadruple Therapy: A Systematic Review and Noninferiority Meta‐Analysis. Journal of Gastroenterology and Hepatology, 41(9), 2545-2556. https://doi.org/10.1111/jgh.70565

Vancouver

Passos PRC, Filho VOC, Noronha MM, Maia MCB, Cançado GGL. Eradication of Helicobacter pylori With Vonoprazan–Amoxicillin Dual Therapy as an Alternative for Bismuth‐Based Quadruple Therapy: A Systematic Review and Noninferiority Meta‐Analysis. Journal of Gastroenterology and Hepatology. 2026;41(9):2545-2556. doi:10.1111/jgh.70565

BibTeX
@article{Passos2026,
  author = {Passos, Pedro Robson Costa and Filho, Valbert Oliveira Costa and Noronha, Mariana Macambira and Maia, Melissa Cortez Braga and Cançado, Guilherme Grossi Lopes},
  title = {Eradication of Helicobacter pylori With Vonoprazan–Amoxicillin Dual Therapy as an Alternative for Bismuth‐Based Quadruple Therapy: A Systematic Review and Noninferiority Meta‐Analysis},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  volume = {41},
  number = {9},
  pages = {2545--2556},
  doi = {10.1111/jgh.70565}
}
Kostenlos starten →